As per the research report titled ‘Global Next-Generation Cancer Diagnostics Market 2022-2028’, available with MarketStudyReport, global next-generation cancer diagnostics market is projected to register a CAGR of 18.9% during the review period and reach a valuation of USD 19,777 million by the end of 2028.

The expansion of global next-generation cancer diagnostics market is backed by a steep decline in the cost of genetic sequencing, rising incidences of cancer, advancements in cluster chip technology (CTC), and potential applications of CTC in cancer management.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4973412/

Additionally, supportive initiatives by the government, rising expenditure on healthcare infrastructure, and growing demand for preventive medicine are further bolstering industry development.

The study goes on to evaluate the constraints and bottlenecks present in the industrial realm, while discussing the viable alternatives that will assist stakeholders in optimizing their profits.

On top of that, the research also delivers a detailed analysis of worldwide next-generation cancer diagnostics market size, key trends, competitive landscape as well as the influence of the COVID-19 outbreak on growth matrix to provide a better understanding of the market scenario to the stakeholders for the analysis timeframe.

Based on technology, the market is bifurcated into next-generation sequencing (NGS), and polymerase chain reaction (PCR) among others. The PCR (polymerase chain reaction) segment accounted for a substantial revenue share in 2021 and is anticipated to attain a modest valuation during the forecast timeframe.

Speaking of regional landscape, the industry trends and valuable information on lucrative avenues are examined across North America, Europe, Asia-Pacific.

The notable players responsible for amplifying the competitive scope of worldwide next-generation cancer diagnostics industry are Thermo Fisher Scientific, Inc., QIAGEN N.V., Myriad Genetics, Inc., Hologic, Inc., Exact Sciences Corp. (Genomic Health, Inc.), BGI Group, Abbott Laboratories, Sysmex Corporation, OPKO Health, Inc., Illumina, Inc., F. Hoffmann-La Roche AG, Danaher Corporation, and Agilent Technologies, Inc. among others.